PR Newswire BiotechOriginal article
CellOrigin Unveils Two Novel Solid-Tumor Cell Therapy Candidates at ASCO 2026, Partners with Walvax for In Vivo CAR Clinical Trial
ConferenceIn Vivo CARPositive
AI Analysis
Summary
CellOrigin unveiled two novel solid-tumor cell therapy candidates at ASCO 2026 and announced a strategic partnership with Walvax for an in vivo CAR clinical trial.
Clinical Trial Data
Outcome Details
CellOrigin unveiled two novel solid-tumor cell therapy candidates and announced partnership with Walvax for in vivo CAR clinical trial
Importance:5/10
Sentiment:
0.60
cell therapysolid tumorsCAR-Tclinical trialpartnershipASCO 2026
Read the original article
Published by PR Newswire Biotech on July 31, 2026 6:15 AM